Navignostics AG

Startup

Navignostics is a spin-off company from the University of Zurich, founded in April 2022, which is leveraging spatial single-cell proteomics to perform advanced analyses of tumor samples. As a start–up active in the personalized medicine field, Navignostics strives to provide innovative solutions to identify the best possible treatment for each cancer patient. In addition, Navignostics provides advanced services to pharmaceutical companies to accelerate cancer drug development and to contribute to companion diagnostic development.